Lupin and Natco get FDA approval for Eribulin Mesylate Injection
The U.S. FDA has approved Lupin and Natco’s generic version of Halaven Injection, a cancer therapy with annual U.S. sales of approximately $43.7 million.
Lupin
Lupin gets U.S. FDA approval for Glycerol Phenylbutyrate Oral Liquid
Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, is bioequivalent to the reference listed drug (RLD), Ravicti® Oral Liquid, 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC.
Lupin launches Dapagliflozin tablets in the United States
The tablets are bioequivalent to Farxiga®.
Lupin CEO Vinita Gupta named to 2026 CNBC Changemakers List
The annual CNBC Changemakers list honors women whose leadership is delivering measurable business impact and long-term change.
Lupin launches first PrecisionSphere long-acting injectable in the U.S.
This technology allows for easier injection with smaller needles and more consistent drug concentrations.
Lupin announces strategic partnership program to expand reach of its long-acting injectable platform
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles.
Lupin to build $250 million manufacturing facility in Florida
The facility will produce vital respiratory medicines and bolster the company’s role as a global respiratory leader.
Lupin launches ipratropium bromide nasal solution
Ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals.